Literature DB >> 22908887

Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy.

Cecilia T Costiniuk1, Colin Kovacs, Jean-Pierre Routy, Joel Singer, Sanjay Gurunathan, Rafick-Pierre Sekaly, Jonathan B Angel.   

Abstract

Although there is discordance between human immunodeficiency virus (HIV) blood plasma and seminal plasma viral loads (VL), little is known about the dynamics of VL rebound in these compartments upon discontinuation of highly active antiretroviral therapy (HAART). Therefore, we sought to examine the relationship between blood and semen VL rebound after discontinuation of HAART. Participants in this substudy were men enrolled from two centers of a multicenter, placebo-controlled randomized trial of HIV therapeutic vaccination using ALVAC with or without Remune. With at least 2 years of sustained virologic suppression and following a 20-week vaccination course, subjects underwent structured HAART interruption. Fourteen men provided semen samples. Seven to 12 weeks after HAART interruption, all 14 men had detectable blood VLs whereas 8 of 14 had detectable seminal VLs. There was a significant correlation between blood and seminal VLs (Spearman r=0.58, p=0.03) at the time of semen collection. An earlier time to detectable blood VL after HAART interruption was associated with higher seminal VL (Spearman r=-0.64, p=0.02). These findings support the compartmentalization of HIV and underscore the importance of understanding the genital tract as an HIV reservoir in the quest to minimize HIV transmission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22908887      PMCID: PMC3552161          DOI: 10.1089/AID.2011.0343

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

1.  Concordance between semen-derived HIV-1 proviral DNA and viral RNA hypervariable region 3 (V3) envelope sequences in cases where semen populations are distinct from those present in blood.

Authors:  Rebecca Curran; Jonathan K Ball
Journal:  J Med Virol       Date:  2002-05       Impact factor: 2.327

2.  Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.

Authors:  Deborah Donnell; Jared M Baeten; James Kiarie; Katherine K Thomas; Wendy Stevens; Craig R Cohen; James McIntyre; Jairam R Lingappa; Connie Celum
Journal:  Lancet       Date:  2010-05-26       Impact factor: 79.321

3.  Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group.

Authors:  M S Cohen; I F Hoffman; R A Royce; P Kazembe; J R Dyer; C C Daly; D Zimba; P L Vernazza; M Maida; S A Fiscus; J J Eron
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

4.  Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

Authors:  Tae-Wook Chun; J Shawn Justement; Danielle Murray; Claire W Hallahan; Janine Maenza; Ann C Collier; Prameet M Sheth; Rupert Kaul; Mario Ostrowski; Susan Moir; Colin Kovacs; Anthony S Fauci
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

5.  Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy.

Authors:  Xia Jin; Murugappan Ramanathan; Shady Barsoum; Geoffrey R Deschenes; Lei Ba; James Binley; Daryl Schiller; Daniel E Bauer; Donald C Chen; Arlene Hurley; Lucette Gebuhrer; Raphaelle El Habib; Pierre Caudrelier; Michel Klein; Linqi Zhang; David D Ho; Martin Markowitz
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma.

Authors:  G Lorello; C la Porte; R Pilon; G Zhang; T Karnauchow; P MacPherson
Journal:  HIV Med       Date:  2009-06-08       Impact factor: 3.180

7.  Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI.

Authors:  Kyeong-Ae Kim; Maral Yolamanova; Onofrio Zirafi; Nadia R Roan; Ludger Staendker; Wolf-Georg Forssmann; Adam Burgener; Nathalie Dejucq-Rainsford; Beatrice H Hahn; George M Shaw; Warner C Greene; Frank Kirchhoff; Jan Münch
Journal:  Retrovirology       Date:  2010-06-23       Impact factor: 4.602

8.  Persistent HIV RNA shedding in semen despite effective antiretroviral therapy.

Authors:  Prameet M Sheth; Colin Kovacs; Kimdar S Kemal; R Brad Jones; Janet M Raboud; Richard Pilon; Charles la Porte; Mario Ostrowski; Mona Loutfy; Harold Burger; Barbara Weiser; Rupert Kaul
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

9.  The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection.

Authors:  Nadia R Roan; Jan Münch; Nathalie Arhel; Walther Mothes; Jason Neidleman; Akiko Kobayashi; Karen Smith-McCune; Frank Kirchhoff; Warner C Greene
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

10.  Semen-derived amyloid fibrils drastically enhance HIV infection.

Authors:  Jan Münch; Elke Rücker; Ludger Ständker; Knut Adermann; Christine Goffinet; Michael Schindler; Steffen Wildum; Raghavan Chinnadurai; Devi Rajan; Anke Specht; Guillermo Giménez-Gallego; Pedro Cuevas Sánchez; Douglas M Fowler; Atanas Koulov; Jeffery W Kelly; Walther Mothes; Jean-Charles Grivel; Leonid Margolis; Oliver T Keppler; Wolf-Georg Forssmann; Frank Kirchhoff
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

View more
  4 in total

Review 1.  The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.

Authors:  Sharilyn Almodovar
Journal:  Viral Immunol       Date:  2014-05-05       Impact factor: 2.257

2.  Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

Authors:  Thomas W North; Andradi Villalobos; Selwyn J Hurwitz; Jesse D Deere; Joanne Higgins; Payel Chatterjee; Sijia Tao; Robert C Kauffman; Paul A Luciw; James J Kohler; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

3.  Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Authors:  Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

4.  Large Isoform of Mammalian Relative of DnaJ is a Major Determinant of Human Susceptibility to HIV-1 Infection.

Authors:  Yu-Ping Chiang; Wang-Huei Sheng; Pei-Lan Shao; Ya-Hui Chi; Yi-Ming Arthur Chen; Szu-Wei Huang; Hsiu-Ming Shih; Luan-Yin Chang; Chun-Yi Lu; Shan-Chwen Chang; Chien-Ching Hung; Li-Min Huang
Journal:  EBioMedicine       Date:  2014-10-07       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.